Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

Pancreatic Cancer

FDA Approves Daraxonrasib, First RAS‑Targeted Pill for Advanced Pancreatic Cancer

Phase III evidence showing nearly doubled survival establishes a new class of RAS inhibitors for patients with few options.

New Oral Drug Nearly Doubles Survival for Treated Metastatic Pancreatic Cancer

NEJM Study and FDA Access Advance Daraxonrasib for Pancreatic Cancer

FDA Authorizes Early Access to Daraxonrasib for Pancreatic Cancer Patients

Revolution Medicines Drug Nearly Doubles Survival in Phase 3 Pancreatic Cancer Trial